Compound class:
Synthetic organic
Comment: The discovery of the TL-77, is described in [2] (and also as compound 9a in [1]). This compound is reported to have improved oral bioavailability compared to rigosertib, and represents a lead anti-mitotic, anti-cancer agent with potential for further development.
|
|